Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.
NCT ID: NCT01959932
Last Updated: 2020-03-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
169 participants
INTERVENTIONAL
2013-06-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting
NCT01970982
Reduced Exposure to HPHC in Smokers Switching From Cigarettes to Different Versions of THS
NCT05599451
Reduction of Exposure, Inflammation, and Oxidative Stress Following At Least 2 Years of Switching to THS Use Compared to Cigarette Smoking
NCT05385055
Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks
NCT02396381
Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article
NCT00812279
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tobacco Heating System (THS 2.2)
Ad libitum use of THS 2.2 for 5 days in confinement
Tobacco Heating System (THS 2.2)
THS 2.2 ad libitum for 5 days in confinement
Smoking abstinence (SA)
Abstinence from smoking for 5 days in confinement
Smoking abstinence (SA)
SA for 5 days in confinement
Conventional cigarette (CC)
Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
Conventional cigarette (CC)
Subject's own preferred brand of CC ad libitum for 5 days in confinement
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tobacco Heating System (THS 2.2)
THS 2.2 ad libitum for 5 days in confinement
Smoking abstinence (SA)
SA for 5 days in confinement
Conventional cigarette (CC)
Subject's own preferred brand of CC ad libitum for 5 days in confinement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current healthy smoker as judged by the Principal Investigator.
* Subject has smoked at least 10 commercially available non-menthol CCs per day (no brand restrictions) for the last 4 weeks.
* Subject has smoked for at least the last 3 consecutive years.
* Subject does not plan to quit smoking in the next 3 months.
Exclusion Criteria
* Subject has received medication within 14 days or within 5 half-lives of the medication (whichever is longer), which has an impact on cytochrome P450 1A2 (CYP1A2) or cytochrome P450 2A6 (CYP2A6) activity.
* Female subject is pregnant or breast feeding.
* Female subject does not agree to use an acceptable method of effective contraception.
21 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Philip Morris Products S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christelle Haziza, PhD
Role: STUDY_CHAIR
Philip Morris Products S.A.
Katarzyna Jarus-Dziedzic, MD PhD
Role: PRINCIPAL_INVESTIGATOR
BioVirtus Research Site
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BioVirtus Research Site Sp. z o.o.
Kajetany, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZRHR-REXC-03-EU
Identifier Type: OTHER
Identifier Source: secondary_id
ZRHR-REXC-03-EU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.